FDA向广东碧素堂发出警告信320-27-11,指其未回应记录要求并在防晒霜使用已撤销着色剂
FDA警告信:广东碧素堂生物科技有限公司
美国FDA于2026年10月27日向广东碧素堂生物科技有限公司发出警告信(编号320-27-11),指其未回应依据FD&C法案704(a)(4)条发出的记录要求。
2026年10月27日,美国FDA向广东碧素堂生物科技有限公司发出警告信(编号320-27-11)。这封警告信的起点不是检查,是“不回话”:FDA在5月1日按704(a)(4)条索要记录,邮件发了、电话打了、UPS寄的书面要求也由贵方代表签收了,三次沟通都没有回应。7月31日,FDA把这家企业所有拟进口美国的药品列入进口警示66-79。原函中英对照如下:
October 27, 2026
2026年10月27日
Reference number: 320-27-11
参考编号:320-27-11
Delivery: VIA UNITED PARCEL SERVICE WITH RETURN RECEIPT REQUESTED / VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED
送达方式:联合包裹(UPS)寄送并要求回执/电子邮件发送并要求阅读与送达回执
To: Mr. Jianfang Chen, CEO
收件人:陈建方先生,首席执行官
Guangdong Bisutang Biotechnology Co., Ltd.
广东碧素堂生物科技有限公司(FDA原文:Guangdong Bisutang Biotechnology Co., Ltd.)
Floor 1-5, One of No. 15 (Factory Building 1-1), Industrial Cluster Development Zone, Xiamao Town, Zhaoqing, 526243, China
中国广东省肇庆市四会市下茆镇产业聚集发展区自编号15号(厂房1-1)之一,1至5层,邮编526243
FDA Establishment Identifier (FEI): 3031796296
FDA企业识别号(FEI):3031796296
Issuing Office: Center for Drug Evaluation and Research (CDER)
发文机构:药品审评与研究中心(CDER)
致陈建方先生:
This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.
本警告信告知贵方:美国FDA在审阅贵方设施提交的记录时发现了重大违规,并给予贵方整改机会。请立即处理本函所述任何违规,不得拖延,包括确保配置充足资源以彻底解决违规并防止再次发生。本函并非贵方产品相关违规的完整清单。确保贵公司符合联邦法律(包括FDA法规)的全部要求,是贵方的责任。未能充分处理任何违规,可能导致FDA在不另行通知的情况下采取监管措施。
FDA Review
FDA审查
Violations were identified and documented during review of your drug manufacturing facility, Guangdong Bisutang Biotechnology Co., Ltd., FDA Establishment Identifier (FEI) 3031796296. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.
在对贵方药品生产设施——广东碧素堂生物科技有限公司(FDA企业识别号FEI 3031796296)——的审阅中,发现并记录了违规。该审阅是FDA依据法定权限和公共卫生职责开展的,旨在保护公众免受不安全、无效和劣质药品之害。
Your facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products, including sunscreen.
贵方设施在FDA注册为非处方药(OTC)生产商,产品包括防晒霜。
A review of import records showed multiple shipments of products into the United States, which declared Guangdong Bisutang Biotechnology Co., Ltd., as the manufacturer. On May 1, 2026, FDA sent an initial electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file and to your U.S. Agent. This request went unanswered as did numerous follow-up requests, including a second electronic request sent on May 19, 2026, and a separate phone call to the listed U.S. Agent of record on May 27, 2026. Additionally, FDA sent a follow-up written request for such records and other information by United Parcel Service (UPS) on May 28, 2026. Delivery of the UPS package was confirmed by signature of your facility representative, but you failed to respond to any of these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.
对进口记录的审查显示,有多批产品发运至美国,且申报的生产商为广东碧素堂生物科技有限公司。2026年5月1日,FDA依据《联邦食品、药品和化妆品法案》(FD&C法案)第704(a)(4)条(21 U.S.C. 374(a)(4)),向贵方注册档案中提供的联系邮箱及贵方美国代理人发出首份电子记录及其他信息要求。该要求未获答复;其后多次跟进亦未获答复,包括2026年5月19日发出的第二份电子要求和2026年5月27日致登记在册美国代理人的单独电话。此外,FDA于2026年5月28日通过联合包裹(UPS)寄送了关于上述记录及其他信息的书面跟进要求。UPS包裹的投递已由贵方设施代表签字确认,但贵方未对上述任何沟通尝试作出回应,也未提供所要求的记录或其他信息。依据第704(a)(4)条,FDA的要求及后续沟通已充分、清晰地描述了所需记录。
It is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as manufactured at your facility.
拒绝按第704(a)条要求允许查阅或复制任何记录,属于FD&C法案第301(e)条(21 U.S.C. 331(e))所禁止的行为。由于贵公司未回应第704(a)(4)条记录要求及相关沟通尝试,FDA无从了解贵方设施所列药品的质量保证水平。
FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-79 on July 31, 2026.
2026年7月31日,FDA将贵公司拟进口至美国的所有药品和药品制品列入进口警示66-79。
Use of Cancelled Color Additive Ext. D&C Yellow No. 5
使用已撤销的着色剂Ext. D&C Yellow No. 5
Based on your drug product listing we determined that your “XUEYI SKIN CARE” sunscreen is adulterated under section 501(a)(4)(A) of the FD&C Act as this FDA-listed drug product bears or contains a color additive that is unsafe within the meaning of section 721 of the FD&C Act, 21 U.S.C. 379e. Specifically, your “XUEYI SKIN CARE” sunscreen drug product contains the cancelled color additive CI 11680 (also known as Ext. D&C Yellow No. 5). In 1966, FDA cancelled the certification and delisted Ext D&C Yellow No. 5 due to lack of safety data from any manufacturer. Under 21 CFR 81.30(d), using Ext D&C Yellow No. 5 after October 4, 1966, results in the drug being adulterated. Your use of a cancelled color additive in your drug product formulation renders it adulterated under 501(a)(4)(A). Accordingly, the introduction or delivery for introduction of “XUEYI SKIN CARE” sunscreen into interstate commerce is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).
根据贵方药品列名信息,我们认定贵方“XUEYI SKIN CARE”防晒霜属于FD&C法案第501(a)(4)(A)条意义上的掺假药品,因为该已列名药品带有或含有FD&C法案第721条(21 U.S.C. 379e)意义上不安全的着色剂。具体而言,贵方“XUEYI SKIN CARE”防晒霜含有已撤销的着色剂CI 11680(又称Ext. D&C Yellow No. 5)。1966年,由于没有任何生产商提供安全性数据,FDA撤销了Ext. D&C Yellow No. 5的认证并将其除名。依据21 CFR 81.30(d),1966年10月4日之后使用Ext. D&C Yellow No. 5,将导致药品成为掺假药品。贵方在药品配方中使用已撤销的着色剂,使其依第501(a)(4)(A)条构成掺假。因此,将“XUEYI SKIN CARE”防晒霜引入或交付引入州际贸易,属于FD&C法案第301(a)条(21 U.S.C. 331(a))所禁止的行为。
For more information regarding color nomenclature see the webpage for Regulatory Status of Color Additives at https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=ColorAdditives.
关于着色剂命名的更多信息,见FDA官网“着色剂监管状态”页面:https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=ColorAdditives。
Drug Import Information
药品进口信息
You manufacture both drug and cosmetic products. Based on information from FDA import records, there appear to be discrepancies in the electronic import entry submissions for your products, specifically regarding the failure to correctly declare your drug product listing. Prior to distributing products intended for the United States, you should ensure that the firms shipping or importing your drug products, and the entry filers transmitting the electronic data to U.S. Customs and Border Protection and FDA, are declaring your firm as the manufacturer, as well as using your registration number and product listing number(s). See 21 CFR 1.74(a)(1).
贵方既生产药品也生产化妆品。根据FDA进口记录的信息,贵方产品的电子进口报关申报似乎存在不一致,具体表现为未正确申报药品列名信息。在销售拟销往美国的产品之前,贵方应确保发运或进口贵方药品的企业,以及向美国海关与边境保护局和FDA传输电子数据的报关行,均申报贵公司为生产商,并使用贵方的注册号和产品列名号。参见21 CFR 1.74(a)(1)。
Cosmetics Manufactured for Distribution in the United States
在美国销售的化妆品
In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.
此外,贵方生产的某些产品可能按FD&C法案第201(i)条(21 U.S.C. 321(i))的定义作为化妆品监管。贵方生产的任何化妆品都必须符合适用的法律法规要求,包括FD&C法案。我们指出,依据FD&C法案第301(a)条(21 U.S.C. 331(a)),将掺假或标签不当的化妆品引入或交付引入州际贸易,属禁止行为。
We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.
我们还指出,2022年《化妆品监管现代化法案》(MoCRA)提出了化妆品生产设施必须遵守的新要求。可通过FDA网站www.fda.gov的链接查阅FD&C法案、MoCRA及FDA法规。
Conclusion
结论
FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-79 on July 31, 2026.
2026年7月31日,FDA将贵公司拟进口至美国的所有药品和药品制品列入进口警示66-79。
Until FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at Guangdong Bisutang Biotechnology Co., Ltd., at Floor 1-5, One of No. 15 (Factory Building 1-1), Industrial Cluster Development Zone, Xiamao Town, Zhaoqing into the United States that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). After you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may submit a request to schedule an FDA inspection.
在FDA确认贵方符合CGMP及其他适用要求之前,FDA可暂不批准任何将贵公司列为药品生产商的新申请或补充申请。此外,依据FD&C法案第801(a)(3)条(21 U.S.C. 381(a)(3)),由广东碧素堂生物科技有限公司(中国广东省肇庆市四会市下茆镇产业聚集发展区自编号15号(厂房1-1)之一,1至5层)生产并拟运往美国、疑似掺假或标签不当的产品,可被扣留或拒绝入境。收到本函后,请在15个工作日内书面回复本办公室。针对本函,贵方可提交申请,要求安排FDA检查。
Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your written response with FEI 3031796296 and ATTN: Lynnsey Renn in the letter or in the subject line of the email.
请将书面回复发送至CDER-OC-OMQ-Communications@fda.hhs.gov。请在函件正文或邮件主题中注明FEI 3031796296及收件人ATTN: Lynnsey Renn。
If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.
若贵方认为有材料可证明产品未违反FD&C法案及FDA法规,请一并提交供我方考虑。
FDA posts warning letters to www.FDA.gov.
FDA将警告信公布于www.FDA.gov。
Sincerely,
/S/
Francis Godwin
Director
Office of Manufacturing Quality
Office of Compliance
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
此致
(签名)
Francis Godwin
主任
生产质量办公室
合规办公室
药品审评与研究中心
美国食品药品监督管理局
抄送:Faye Liang & Clare Ho;美国代理人;(b)(4)
¹ 注意不要与名称相近但仍在FDA列名清单内的着色剂食品、药品和化妆品(FD&C)Yellow 5混淆。
(译注一:企业名称。FDA警告信所列英文名为 Guangdong Bisutang Biotechnology Co., Ltd.,对应工商登记名称“广东碧素堂生物科技有限公司”(统一社会信用代码91441284MAC2LXFA20,法定代表人陈建方),注册地址与函中地址一致。英文“Biotechnology”对应中文“生物科技”。本稿中文名以工商登记为准。)
(译注二:文中(b)(4)为FDA依据《信息自由法》第4项豁免所作的脱敏处理。译文仅供学习参考,如与英文原文有歧义,以FDA原文为准。)
来源:制药经理人 · mp.weixin.qq.com